Mallinckrodt, Endo Merger To Create Pharma Entity Valued At $7 Billion
Mallinckrodt and Endo are merging in a $6.7 billion deal, with a pro forma NYSE listing and $900 million in financing.
Drugmakers Mallinckrodt and Endo to Merge in Nearly $7 Billion Deal
(Reuters) - Mallinckrodt and Endo, drugmakers with a shared history of facing U.S. opioid litigation, have agreed to merge in ...
Drugmakers Mallinckrodt, Endo to Merge, Plan NYSE Listing
Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.
BioWorld1d
Endo the line: Mallinckrodt merger worth $6.7B
The pairing of Mallinckrodt plc and Endo Inc. is expected to create a pharma heavyweight that will generate $3.6 billion in 2025 revenue after the duo combines their generic pharmaceuticals businesses ...
Mallinckrodt, Endo Merger to Create Diversified Pharmaceuticals Firm
Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S ...
EMBO Press5d
Surface-mediated bacteriophage defense incurs fitness tradeoffs for interbacterial antagonism
Bacteria navigate tradeoffs between phage resistance and interbacterial competition. This study reveals that while LPS ...
pharmaphorum2d
Endo files for bankruptcy as it agrees opioid settlement
Endo's slide into bankruptcy follows in the footsteps of Purdue Pharma – which filed in 2019 but is still negotiating opioid settlement and corporate restructuring terms – as well as ...
eLife3d
Brief disruption of activity in a subset of dopaminergic neurons during consolidation impairs long-term memory by fragmenting sleep
Learn more about eLife assessments Sleep disturbances are associated with poor long-term memory (LTM) formation, yet the underlying cell types and neural circuits involved have not been fully decoded.